SWHR Recommends ICER Delay Report on Endometriosis Treatments

In comments to the Institute for Clinical and Economic Review (ICER), SWHR recommended the organization delay finalizing its draft evidence report assessing new endometriosis therapies until they have been more thoroughly studied by Food and Drug Administration (FDA). Examining the draft report in detail, SWHR noted areas where ICER’s methodology, modeling techniques, and key inputs could be refined.

SWHR pointed out the limitations within the draft evidence report that make a clear assessment of the new therapies difficult. For example, ICER’s analysis compared the cost-effectiveness of elagolix to no treatment (i.e., placebo) and was unable to compare to other treatments due to lack of data. Delaying the report until more comprehensive studies are completed would allow ICER to produce a more thorough assessment comparing the cost-effectiveness of treatments. SWHR also made recommendations to ICER for improving or refining future analyses.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

In comments to the Institute for Clinical and Economic Review (ICER), SWHR recommended the organization delay finalizing its draft evidence report assessing new endometriosis therapies until they have been more thoroughly studied by Food and Drug Administration (FDA). Examining the draft report in detail, SWHR noted areas where ICER’s methodology, modeling techniques, and key inputs could be refined.

SWHR pointed out the limitations within the draft evidence report that make a clear assessment of the new therapies difficult. For example, ICER’s analysis compared the cost-effectiveness of elagolix to no treatment (i.e., placebo) and was unable to compare to other treatments due to lack of data. Delaying the report until more comprehensive studies are completed would allow ICER to produce a more thorough assessment comparing the cost-effectiveness of treatments. SWHR also made recommendations to ICER for improving or refining future analyses.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

SWHR’s ICER Engagement

Blog Post
SWHR Releases Updated Health Care Value Assessment Principles
Health care value assessment frameworks are tools that can be used to measure the value of health interventions and treatments, with the potential to inform coverage and reimbursement or treatment decisions. However, “value” is not one-size-fits-all. It varies based on an individual’s personal circumstances and life stages or across diseases and conditions; can span clinical... Read more »
Policy Engagement
SWHR’s 2022 Health Care Value Assessment Principles
In 2019, SWHR conceived a set of principles to help ensure value frameworks and assessments reflected factors relevant to women in the ongoing improvement of their health. This year, SWHR has revisited and updated this framework to reflect the ongoing shift in how the U.S. health care system delivers and pays for care. By revisiting... Read more »
Blog Post
Women’s Health Policy Agenda Expands Focus Areas for 2022
The Society for Women’s Health Research (SWHR) recently launched its Women’s Health Policy Agenda for 2022. Outlining the policy priorities of SWHR across five key areas—public health, research and clinical trials, lifespan issues, coverage and access, and the biomedical research workforce—the Policy Agenda builds off SWHR’s inaugural Policy Agenda and aims to serve as a... Read more »
Blog Post
Integrating Women into Health Care Research, Quality Improvement, and Value Assessment
Across research and health policy, the unique needs of women as patients, caregivers, and primary health care decision-makers for their families are receiving more attention.
Blog Post
Women and Value Assessment: Striving to Capture the Patient Experience
SWHR hosted three value assessment experts at its recent policy meeting to discuss the integration of women’s health priorities into assessments of new health care innovations.
Blog Post
ICER’s Value Framework: A Work in Progress for Women’s Health
ICER's updated value assessment framework embraces several of SWHR’s recommendations, but more work remains to adequately evaluate the value of health care interventions for women.
Blog Post
No ‘Best’ Framework for Assessing Value of Health Care Innovations, NPC Report Says
A report from the National Pharmaceutical Council (NPC) concludes that there is no “best” framework for determining the value of a health care product.
Blog Post
SWHR Develops Principles to Ensure Health Care Value Assessments Work for Women
When a new health care innovation comes to market, how do patients, health care providers, and health care payers determine its value?
Policy Engagement
SWHR Recommendations on ICER’s 2020 Value Assessment Framework
SWHR provided recommendations to the Institute for Clinical and Economic Review (ICER) on proposed changes to its 2020 value assessment framework to ensure it supports optimal health outcomes for women.